Reduced-dose HHT
Phase 2Small molecule
Ascentage Pharma Group Inc.Reduced-dose HHT is one of 13 small molecule programs targeting Relapsed/Refractory AML. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Relapsed/refractory AML
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Venclexta
AbbVieApproved
Leustatin
EMD SeronoApproved
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Luye
Ascentage Pharma Group Inc.Phase 2
Jakafi
IncytePhase 1
Lisaftoclax
Ascentage Pharma Group Inc.Phase 2
Reduced-dose HHT
Ascentage Pharma Group Inc.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reduced-dose HHT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company